These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 9607628)
1. Molecular oncogene markers and their significance in cutaneous malignant melanoma. Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628 [TBL] [Abstract][Full Text] [Related]
2. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497 [TBL] [Abstract][Full Text] [Related]
3. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481 [TBL] [Abstract][Full Text] [Related]
4. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma. Böni R; Bantschapp O; Müller B; Burg G Dermatology; 1998; 196(3):288-91. PubMed ID: 9621133 [TBL] [Abstract][Full Text] [Related]
12. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075 [TBL] [Abstract][Full Text] [Related]
13. [Cutaneous malignant melanoma of the head and neck with intermediate tumor thickness: the role of elective lymph node dissection for clinical stage I]. Wenzel S; Sagowski C; Neuber K; Kehrl W; Metternich FU Laryngorhinootologie; 2003 Jan; 82(1):19-24. PubMed ID: 12548460 [TBL] [Abstract][Full Text] [Related]
14. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Gershenwald JE; Mansfield PF; Lee JE; Ross MI Ann Surg Oncol; 2000 Mar; 7(2):160-5. PubMed ID: 10761797 [TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience. Fairbairn NG; Orfaniotis G; Butterworth M J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263 [TBL] [Abstract][Full Text] [Related]
16. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Lee RJ; Gibbs JF; Proulx GM; Kollmorgen DR; Jia C; Kraybill WG Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):467-74. PubMed ID: 10661355 [TBL] [Abstract][Full Text] [Related]
17. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Slingluff CL; Stidham KR; Ricci WM; Stanley WE; Seigler HF Ann Surg; 1994 Feb; 219(2):120-30. PubMed ID: 8129482 [TBL] [Abstract][Full Text] [Related]
18. Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence. Mendenhall WM; Shaw C; Amdur RJ; Kirwan J; Morris CG; Werning JW Am J Otolaryngol; 2013; 34(4):320-2. PubMed ID: 23375588 [TBL] [Abstract][Full Text] [Related]
19. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. White RR; Stanley WE; Johnson JL; Tyler DS; Seigler HF Ann Surg; 2002 Jun; 235(6):879-87. PubMed ID: 12035046 [TBL] [Abstract][Full Text] [Related]
20. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma. Brountzos EN; Panagiotou IE; Bafaloukos DI; Kelekis DA Oncol Rep; 2003; 10(2):505-10. PubMed ID: 12579298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]